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Last summer and fall marked the 10-year anniversary of the 
public health warnings and the eventual withdrawal of prod-
ucts containing fenfluramine or dexfenfluramine.  There was 
an explosion of prescribing of antiobesity agents in the mid-
1990’s, mostly fueled by the increased prescribing of fen-
phen.1 Much of this use was long-term; forty-six percent of 
those taking fen-phen and 33% of those taking fenfluramine 
or dexfenfluramine alone reported taking it for more than 12 
weeks.2  Off-label use of these drugs was rampant.  
Recall, however, that fenfluramine received FDA approval in 
1973 for the short-term management of obesity.3  FDA ap-
proval of dexfenfluramine in 1996 for longer-term weight 
management therapy provided opportunities for increased 
exposure to fenfluramines. This dramatic change in clinical 
management of obesity precipitated the increased reports of 
incident cardiac valvulopathy, not the traditional, short-term, 
FDA-approved use of fenfluramines.  Connolly et al.4 re-
ported pathologic evidence of valvular plaques resembling 
serotonin-mediated carcinoid syndrome among cases ex-
posed to fenfluramine-phentermine combination therapy. 
Following this study, the FDA reported an estimated 32.8% 
prevalence of valvular disease among individuals exposed to 
fenfluramines.2  But, 10 years later, one still wonders why 
was cardiac valve regurgitation a new adverse event phe-
nomenon when fenfluramine was on the market for over 
twenty years? 
Of equal concern was the public’s reaction to the unfolding 
risks of these products.  On July 8, 1997, the FDA issued a 
public health advisory to health care professionals emphasiz-
ing the impact of fenfluramine and dexfenfluramine on users’ 
hearts.5 The FDA advisory stated “the FDA reminds all health 
care practitioners that the safety and effectiveness of the use 
of fenfluramine and phentermine in combination have not 
been established and that serious concerns about the safety of 
such combined use have been raised.” Despite the warnings 
and recommendations, many users did not discontinue use 
immediately. Of those individuals taking drugs containing 
fenfluramine or dexfenfluramine as of May 1997, it is esti-
mated that approximately one-third stopped taking them dur-
ing July and September, one-third stopped taking the pills in 
September and October, and the remaining one-third stopped 
taking the pills over the next 13 months.2  Given the extensive 
coverage in the media and lay press, that this proportion of 
users continued to take weight loss medications containing 
fenfluramine or dexfenfluramine months after they were re-
moved from the market in the United States is of great con-
cern. 
The amplification of risk associated with long-term use sug-
gests off-label use warrants safety monitoring and enforce-
ment by FDA.  Approvals for longer-term use of a particular 
drug such as dexfenfluramine should accompany clinical trial 
data regarding safety and efficacy of continuous treatment. 
Thus, monitoring of how medications are actually used in 
clinical practices post-marketing is warranted. 
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The piece for this edition of Scribe focuses on the phentermine and fenfluramine story.  This edition comes to you from two students 
in my advanced pharmacoepidemiology course, shortened significantly to meet the needs of this column.  I welcome contributions 
which stay true to the theme of reflecting and learning about past challenges in pharmacoepidemiology.   
Please forward ideas to : Kate_Lapane@brown.edu .           
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A few questions remain: 
Today, would the US public heed FDA warnings? 
Has the scientific community learned to work in in-
novative ways with the FDA to investigate the safety 
of medications when off-label use is rampant? 
Are our surveillance systems adequate to detect risks 
quickly when new combinations of medications are 
used or medications are used in ways not envisioned 
when approved for marketing? 
With particular regard to anti-obesity agents, are 
manufacturers designing trials to mimic how these 
medications are likely to be used? 
Given the increases in obesity over the past decades 
in the United States and across the globe, there will 
not be a shortage of patients seeking prescription and 
OTC weight loss remedies over the coming decades. 
It is of extreme public health importance that we 
strive to insure the safety of these products and their 
use, especially given the number of patients who 
currently take prescription weight loss medications 
and the number who may take them in the future. 
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Do you have artistic talents 
or a creative spark?  
 
In anticipation of the 25th anniversary 
celebration in 2009, we are pleased to 
announce a LOGO contest.   
 
The winning designs will be used on the 
mid-year and annual t-shirts, the web, 
and possibly on our stationary for the 
25th year.  
 
The logo can be both text and images.  
 
Please send your ideas and logos 
by April 1, 2008 to: 
Susan.sacks@roche.com and 
Kate_Lapane@brown.edu.   
